Fat jabs and Mounjaro: the straight answers

You've heard the phrase everywhere, here's what's actually in the pen

The term "fat jab" started in the tabloids and stuck, mostly because it captures something real: Mounjaro is a once-weekly subcutaneous injection, made by Eli Lilly, that has produced some of the largest average weight losses ever recorded in clinical trials. The active ingredient is tirzepatide, which mimics two naturally occurring gut hormones (GIP and GLP-1) that signal fullness to the brain and slow the rate at which the stomach empties. The result is that most people using it eat meaningfully less without fighting hunger constantly.

What the shorthand misses is the clinical substance behind it. Mounjaro is a licensed medicine, regulated by the MHRA, prescribed for adults managing obesity or excess weight alongside a weight-related health condition. It is not a cosmetic shortcut and the MHRA has been clear that GLP-1 medicines are not assessed or approved for quick or cosmetic weight loss. The NHS tirzepatide page sets out plainly what the medicine is and is not for. Understanding that distinction matters, because it shapes everything from how you access treatment to what realistic outcomes look like.

If you want to go deeper on the injection itself (how often you use it, where it goes, what the pen looks like) the guide to Mounjaro injections on this site covers the practical side in detail.

The trial results behind the headlines: what "up to 20%" actually means

In SURMOUNT-1, a phase 3 trial published in the New England Journal of Medicine involving 2,539 adults with obesity and no diabetes, participants using tirzepatide 15 mg lost an average of around 20 to 21% of their body weight over 72 weeks alongside a reduced-calorie diet and increased activity. That is a genuinely large figure for a medicine, larger than any previous licensed injectable for weight management in the UK.

The context matters, though. Average results are averages: some people lose considerably more, some less. All participants followed lifestyle guidance throughout. And 72 weeks is over a year of weekly injections, titrated gradually by a prescriber from 2.5 mg upward. These are not results from a four-week trial with a supplement. If you are researching Mounjaro as a fat loss jab, the evidence base is substantial, but the outcomes described in trials reflect people who had clinical supervision throughout.

NICE reviewed this evidence thoroughly before recommending tirzepatide (TA1026, December 2024). Their recommendation sets out the BMI and health-condition thresholds that determine NHS eligibility, which is a separate question from private access, and a question worth reading carefully before assuming you either qualify or don't.

Side effects: the things worth knowing before you start

Most people who use Mounjaro for weight management experience some gastrointestinal side effects, particularly when starting or moving to a higher dose. Nausea, loose stools, constipation, indigestion and burping are the most common. For a lot of people these settle within a week or two; for others they persist longer at certain doses and the prescriber adjusts accordingly. People who want to understand how others have found this process can read real patient experiences on our Mounjaro jabs reviews page, which gives an honest picture of what starting treatment is actually like.

Less common but more serious: the MHRA issued a Drug Safety Update in January 2026 drawing attention to acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines. The signal to act on is severe abdominal pain that reaches through to the back, that warrants urgent medical attention, not a wait-and-see approach. You can report any suspected side effect, including unexpected reactions, through the MHRA Yellow Card scheme.

Mounjaro is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use it. A prescriber runs through all of this during assessment, it is precisely why a prescription process exists rather than over-the-counter access.

How to access Mounjaro through a regulated UK pharmacy

The only legal route to tirzepatide in the UK is through a prescription following a clinical assessment. That assessment looks at your BMI, existing health conditions, current medications, and anything in your history that would affect suitability or dosing. Many people first come to us after reading about skinny jabs and how Mounjaro compares to other injectable options, which is a useful starting point before speaking to a prescriber. A prescriber then decides, not software, not a tick-box form reviewed days later, but a qualified clinician reading your answers the same day.

At nume, that assessment is conducted by a GPhC-registered Independent Prescriber. If you order before noon on a working day and your prescription is approved, the medicine is dispatched the same day and arrives free by tracked DPD delivery the next working day, in plain packaging. One price covers the consultation, prescription, treatment and aftercare, there are no add-on fees. For context on how private treatment costs are structured, the Mounjaro cost guide explains what a legitimate private price typically includes.

If you want to understand all available weight loss treatment options before deciding, that is worth doing. The right medicine is the one a prescriber decides fits your health picture, and our guide to weight loss jabs with Mounjaro walks through what the treatment journey typically involves from first dose to maintenance. When you are ready, check your eligibility and start a free consultation with our clinical team.